Evidence map›Paper›PMID 38687826›Full record

ArticleScience signaling2024

Targeting the postsynaptic scaffolding protein PSD-95 enhances BDNF signaling to mitigate depression-like behaviors in mice.

Xin Shi, Xiao-Zhong Zhou, Gang Chen, Wei-Feng Luo, Chengyu Zhou, Tian-Ju He, Mandar T Naik, Qin Jiang, John Marshall, Cong Cao

Abstract read
In one paragraph

Article in Science signaling, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Antioxidant and Anti-Inflammatory Effects of InhaledPlants (Basel, Switzerland) · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Gαi1/3 Is a Novel Regulatory Target for RANKL Signal Transduction and Osteoporosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xin ShiClinical Research Center of Neurological Disease, Second Affiliated Hospital of Soochow University, Institution of Neuroscience, Soochow University, Suzhou 215123, China.ORCID 0000-0003-4902-5498
Xiao-Zhong ZhouClinical Research Center of Neurological Disease, Second Affiliated Hospital of Soochow University, Institution of Neuroscience, Soochow University, Suzhou 215123, China.ORCID 0000-0003-3076-5090
Gang ChenDepartment of Neurosurgery, First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu, China.ORCID 0000-0002-0758-1907
Wei-Feng LuoClinical Research Center of Neurological Disease, Second Affiliated Hospital of Soochow University, Institution of Neuroscience, Soochow University, Suzhou 215123, China.ORCID 0000-0002-3594-1885
Chengyu ZhouDepartment of Neuroscience, Case Western Reserve University, Cleveland, OH 44106, USA.ORCID 0009-0001-4014-3140
Tian-Ju HeClinical Research Center of Neurological Disease, Second Affiliated Hospital of Soochow University, Institution of Neuroscience, Soochow University, Suzhou 215123, China.
Mandar T NaikDepartment of Molecular Biology, Cell Biology & Biochemistry, Brown University, Providence, RI 02912, USA.ORCID 0000-0002-7016-572X
Qin JiangAffiliated Eye Hospital, Nanjing Medical University, Nanjing 210029, China.ORCID 0000-0003-0541-4635
John MarshallDepartment of Molecular Biology, Cell Biology & Biochemistry, Brown University, Providence, RI 02912, USA.ORCID 0000-0002-9937-0268
Cong CaoClinical Research Center of Neurological Disease, Second Affiliated Hospital of Soochow University, Institution of Neuroscience, Soochow University, Suzhou 215123, China.ORCID 0000-0003-0824-3472

Funding

Development of a lead cyclic-PDZ-Enhancer drug for Anxiety and DepressionR41MH118747 · NIMH · AINGEAL, LLC · PI MARSHALL, JOHN, MATHIOWITZ, EDITH · 2019 to 2020
$911k
NIMH NIH HHS R41 MH118747
6 · The paper itself

Abstract

Signaling mediated by brain-derived neurotrophic factor (BDNF), which is supported by the postsynaptic scaffolding protein PSD-95, has antidepressant effects. Conversely, clinical depression is associated with reduced BDNF signaling. We found that peptidomimetic compounds that bind to PSD-95 promoted signaling by the BDNF receptor TrkB in the hippocampus and reduced depression-like behaviors in mice. The compounds CN2097 and Syn3 both bind to the PDZ3 domain of PSD-95, and Syn3 also binds to an α-helical region of the protein. Syn3 reduced depression-like behaviors in two mouse models of stress-induced depression; CN2097 had similar but less potent effects. In hippocampal neurons, application of Syn3 enhanced the formation of TrkB-Gα

Indexed as

Brain-Derived Neurotrophic FactorDepressionDisks Large Homolog 4 ProteinHippocampusSignal TransductionAnimalsBehavior, AnimalMaleMiceMice, Inbred C57BLMice, KnockoutNeuronsReceptor, trkBStress, PsychologicalBdnf protein, mouseBrain-Derived Neurotrophic FactorDisks Large Homolog 4 ProteinDlg4 protein, mouseReceptor, trkB

Identifiers

PMID38687826
PMCPMC11223518

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.